Form 4: Halozyme Therapeutics Director Barbara Gayle Duncan Reports Stock and Option Grants

Director Barbara Gayle Duncan reports acquisition of stock and option grants from Halozyme Therapeutics.

Summary

• On May 1, 2025, Barbara Gayle Duncan, a director of Halozyme Therapeutics, reported the acquisition of 4,165 shares of common stock and an option to purchase 5,750 shares of common stock.
• The 4,165 shares were granted as restricted stock units (RSUs) under the Issuer's director compensation program, vesting fully on the earlier of May 1, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The stock option grant for 5,750 shares, with an exercise price of $60.03, also vests fully on the earlier of May 1, 2026, or the date of the Issuer's next annual meeting of stockholders, and expires on May 1, 2035.
• Following the reported transactions, Duncan beneficially owns 19,919 shares of common stock and options to purchase 5,750 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices, aligning director interests with shareholders.

Positives

• The grants of stock and options to a director align her interests with those of the shareholders.
• The vesting schedule encourages continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the equity grants.

Industry Context

This filing is a routine disclosure of equity compensation to a company director, which is a common practice in publicly traded companies to incentivize and retain board members. It reflects standard corporate governance practices.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also provide directors with a mix of stock options and restricted stock units as part of their compensation packages.
• The vesting schedules and grant sizes are generally aligned with industry norms to incentivize long-term commitment and align director interests with shareholder value.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.
• The grants have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Halozyme Therapeutics, Director Compensation, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, Duncan, Equity